Status:

COMPLETED

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

Lead Sponsor:

Wills Eye

Collaborating Sponsors:

Optovue

Conditions:

Glaucoma; Drugs

Normal Tension Glaucoma

Eligibility:

All Genders

18-90 years

Phase:

PHASE4

Brief Summary

This study evaluates the possible acute changes in peripapillary blood flow after instillation of antiglaucoma medications in patients with primary open angle glaucoma (POAG), normal tension glaucoma ...

Detailed Description

Reduction of intraocular pressure (IOP) with topical antihypertensive medications is the mainstay of initial treatment in patients with OHTN, POAG, and NTG. Many patients, however, continue to experie...

Eligibility Criteria

Inclusion

  • Diagnosis of ocular hypertension, primary open angle glaucoma, or normal tension glaucoma in the study eye(s)
  • Age 18-90
  • Best corrected visual acuity of 20/60 or better

Exclusion

  • Current use of either brimonidine or timolol
  • Other disease, ophthalmic or systemic, that is likely to significantly affect the OCT test in the study eye(s) including:
  • More than moderate grade cataract that significantly reducing OCTA scan signal level
  • Macular degeneration other than mild drusen or pigmentary changes
  • Diabetic retinopathy other than mild background non proliferative retinopathy
  • Prior or current macular edema
  • Prior laser treatment to the retina
  • Prior retinal detachment
  • Prior central serous retinopathy
  • Prior retinal vein or artery occlusion
  • Prior inflammatory retinopathy or choroidopathy
  • Keratoconus or other corneal ectasia
  • Corneal scarring in central 4 mm
  • Prior penetrating keratoplasty
  • Ischemic optic neuropathy
  • Dementia beyond early/mild memory loss
  • History of cerebrovascular accident
  • History of severe carotid stenosis
  • History of previous ocular surgery other than non-complicated cataract extraction

Key Trial Info

Start Date :

July 10 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 30 2020

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT03323164

Start Date

July 10 2017

End Date

May 30 2020

Last Update

December 31 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Glaucoma Research Center - Wills Eye Hospital

Philadelphia, Pennsylvania, United States, 19107

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study | DecenTrialz